Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents

Pediatric Blood and Cancer

Volumn 45, Issue 6, 2005, Pages 857-860

  Smith, Angela R ^a   Repka, Tanya L ^b   Weigel, Brenda J ^a,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b St Luke's Specialty Clinic   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Antiemetics; Aprepitant; Chemotherapy induced nausea and vomiting (CINV); Neurokinin 1 receptor antagonists; Pediatrics

Indexed keywords

ANTIEMETIC AGENT; APREPITANT; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; IRINOTECAN; LORAZEPAM; METHOTREXATE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON;

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; CHEMOTHERAPY INDUCED EMESIS; CHILDHOOD CANCER; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGH RISK PATIENT; HUMAN; MALE; NAUSEA AND VOMITING; OSTEOSARCOMA; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT;

ADOLESCENT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MORPHOLINES; NAUSEA; RECEPTORS, NEUROKININ-1; TREATMENT OUTCOME;

EID: 26244443909     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20378     Document Type: Article

References (14)

1. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-3098.
2. Campos D, Rodrigues-Pereira J, Reinhardt RR, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone of with dexamethasone alone. J Clin Oncol 2001;19:1759-1767.
3. Van Belle S, Lichinitser MR, Navari RM, et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 2002; 94:3032-3041.
4. Diemunsch P, Grelot L. Potential for substance P antagonists as antiemetics. Drugs 2000;60:533-546.
5. Roila F, Del Favero A, Gralla RJ, et al. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the Perugia Consensus Conference. Ann Oncol 1998;9:811-819.
6. Bleiberg H. A new class of antiemetics: The NK1 receptor antagonists. Curr Opin Oncol 2000;12:284-288.
7. Cocquyt V, Van Belle S, Reinhardt RR, et al. Comparison of L-758,298, a pro-drug for the selective neurokinin-1 antagonist, L754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 2001;37:835-842.
8. deWit R, vanAlphen NM. New developments in the treatment of nausea and vomiting caused by chemotherapy. Nederlands tijdschrift voor Geneeskunde 2003;146:690-694.
9. Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003;97: 2290-2300.
10. Navari RM, Reinhardt RR, Gralla RJ, et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1 receptor antagonist. N Engl J Med 1999;340:190-195.
11. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral NK1 receptor antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-The Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21: 4112-4119.
12. Deleted in proofs.
13. Bountra C, Bunce K, Dale T, et al. Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets. Eur J Pharmacol 1993;249:R3-R4.
14. Guidelines for Emend (aprepitant). Merck & Co, Inc., 2003.